

Anti-CD180 Reference Antibody (Champions Oncology patent anti-CD180)

Catalog # APR11412

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q99467
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-REM-noK
Calculated MW	74179

Additional Information


Target/Specificity	CD180
Expression system	CHO

Protein Information


Name	CD180
Synonyms	LY64, RP105
Function	Pattern recognition receptor predominantly expressed on B- cells, dendritic cells, and certain monocytes/macrophages, structurally resembling Toll-like receptors (TLRs) that plays a role in modulating immune responses (PubMed:15852007). While resembling a TLR, lacks the intracellular TIR (Toll/IL-1R) signaling domain and thus does not directly transduce signals. Instead, modulates immune responses, often in conjunction with other TLRs. For example, in cooperation with MD- 1/LY86, interacts directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligand (PubMed:15852007).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Expressed mainly on mature peripheral B cells. Detected in spleen, lymph node and appendix. Not detected in pre-B and -T cells

Images


Anti-CD180 Reference Antibody (Champions Oncology patent anti-CD180) on SDS-PAGE under reducing (R)



condition. The purity of the protein is greater than 95%.



The purity of Anti-CD180 Reference Antibody (Champions Oncology patent anti-CD180) is 99.7%, determined by SEC-HPLC.



PLVX-puro-CD180-FL cell line were stained with Champions Oncology patent anti-CD180 and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 6.027 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.